Drug Trial News

RSS

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.

1 Sep 2021

UniSA researchers are putting cancer patients at the heart of clinical trials

From bench to bedside, the journey towards new cancer therapies is full of challenges. Clinical trials – where new treatments are tested on people – are vital, but with fewer than five per cent of cancer patients participating worldwide, it’s a long road to travel.

1 Sep 2021

Investigational vaccine does not provide sufficient protection against HIV infection

An investigational HIV vaccine tested in the "Imbokodo" clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women ages 18 to 35 years from five countries.

31 Aug 2021

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

A new study shows that the highly effective mRNA Moderna vaccine designed against the original SARS-CoV-2 strain may lose some efficacy as new variants arise.

30 Aug 2021

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

A new study adds to the data on the optimum interval between the first and second doses of the adenovirus vectored COVID-19 vaccine.

30 Aug 2021

$Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction$

Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction

Until now, patients with heart failure with preserved ejection fraction – the most common type of heart failure in the elderly – have had no access to evidenced-based treatments. For the first time, a large clinical trial led by Prof. Dr. Stefan Anker from Charité – Universitätsmedizin Berlin has identified a drug which has a distinctly positive effect on prognosis. In patients affected by this type of heart failure, the drug – empagliflozin – reduces the risk of hospitalization or cardiovascular death by 21 percent. The results of this research have been published in the New England Journal of Medicine.

28 Aug 2021

$Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction$

Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction

A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.

27 Aug 2021

NIH begins clinical trial to assess extra COVID-19 vaccine dose in people with autoimmune disease

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen.

27 Aug 2021

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

The AIDS Clinical Trials Group, the largest global HIV research network, which has expanded its focus to include evaluating outpatient treatment for COVID-19, today announced positive data for the monoclonal antibody combination therapy BRII-196/BRII-198 from the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies.

27 Aug 2021

Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival

A Phase 2 trial led by City of Hope, a world-renowned research and treatment center for cancer and diabetes, suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial cancer does not extend progression-free survival.

27 Aug 2021

Researchers receive $14 million grant to study the effectiveness of hydrocephalus treatment

Patients diagnosed with idiopathic normal pressure hydrocephalus (iNPH), a type of brain swelling most commonly seen in older adults — and for which the underlying cause is unknown — are typically treated by surgically installing a shunt (drain) to remove the excess fluid associated with the condition.

26 Aug 2021

Could soluble CD24 offer some hope against severe COVID-19?

A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.

26 Aug 2021

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

A combination of metformin and chemoradiation in patients with locally advanced non-small cell lung cancer (LA-NSCLC) was not found to add survival benefit in the NRG Oncology clinical trial NRG-LU001. These results were recently published in JAMA Oncology.

25 Aug 2021

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK.

24 Aug 2021

Antiviral strategy using synthetic peptoid has promising implications for fighting infection

Scientists have manufactured a synthetic form of peptide to combat viral infections, with tests already conducted on HSV-1 as well as SARS-CoV-2.

24 Aug 2021

Lipid-lowering drug TriCor dramatically cuts treatment time for severe COVID-19 patients

The SARS-CoV-2 virus has infected over 165 million people worldwide causing nearly 3.5 million deaths. Recent vaccination efforts have been hindered by multiple coronavirus variants that challenge current vaccines.

23 Aug 2021

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

19 Aug 2021

Children’s Hospital Colorado helps prove safety and efficacy of CF treatment in younger pediatric patients

Researchers at the Children's Hospital Colorado Breathing Institute, the largest pediatric cystic fibrosis (CF) clinical care center in the U.S., participated in the pivotal international multi-center Phase 3 clinical trial, sponsored by Vertex Pharmaceuticals Incorporated, leading to FDA approval of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor), a highly effective CF treatment, for patients ages 6 through 11 who have at least one copy of the F508del mutation.

17 Aug 2021

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

An innovative new study is trialing whether giving aspirin, commonly used as pain relief, alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer.

17 Aug 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.

17 Aug 2021

Previous
1
...
51
52
53
54
55
56
57
...
1149
Next

Drug Trial News

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

UniSA researchers are putting cancer patients at the heart of clinical trials

Investigational vaccine does not provide sufficient protection against HIV infection

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction

Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction

NIH begins clinical trial to assess extra COVID-19 vaccine dose in people with autoimmune disease

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival

Researchers receive $14 million grant to study the effectiveness of hydrocephalus treatment

Could soluble CD24 offer some hope against severe COVID-19?

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

Antiviral strategy using synthetic peptoid has promising implications for fighting infection

Lipid-lowering drug TriCor dramatically cuts treatment time for severe COVID-19 patients

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody

Children’s Hospital Colorado helps prove safety and efficacy of CF treatment in younger pediatric patients

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News